Cita APA

Mall, M., Wainwright, C., Legg, J., Chilvers, M., Dittrich, A., & Gartner, S. (2025). Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: Results from a 96-week open-label extension study.

Citación estilo Chicago

Mall, Marcus, Claire Wainwright, Julian Legg, Mark Chilvers, Anna-Maria Dittrich, y Silvia Gartner. Elexacaftor/tezacaftor/ivacaftor in Children Aged ≥6 years With Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: Results From a 96-week Open-label Extension Study. 2025.

Cita MLA

Mall, Marcus, et al. Elexacaftor/tezacaftor/ivacaftor in Children Aged ≥6 years With Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: Results From a 96-week Open-label Extension Study. 2025.